CA2796884A1 - Forme posologique orale a liberation regulee amelioree - Google Patents

Forme posologique orale a liberation regulee amelioree Download PDF

Info

Publication number
CA2796884A1
CA2796884A1 CA2796884A CA2796884A CA2796884A1 CA 2796884 A1 CA2796884 A1 CA 2796884A1 CA 2796884 A CA2796884 A CA 2796884A CA 2796884 A CA2796884 A CA 2796884A CA 2796884 A1 CA2796884 A1 CA 2796884A1
Authority
CA
Canada
Prior art keywords
bupropion
pellet
pharmaceutically acceptable
acceptable salt
sustained release
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2796884A
Other languages
English (en)
Inventor
Boyong Li
Chih-Ming Chen
Xiu Xiu Cheng
Avinash Nangia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Andrx Pharmaceuticals LLC
Original Assignee
Andrx Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Andrx Pharmaceuticals LLC filed Critical Andrx Pharmaceuticals LLC
Publication of CA2796884A1 publication Critical patent/CA2796884A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
CA2796884A 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree Abandoned CA2796884A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US26745701P 2001-02-08 2001-02-08
US26745601P 2001-02-08 2001-02-08
US60/267,456 2001-02-08
US60/267,457 2001-02-08
CA2685214A CA2685214C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2685214A Division CA2685214C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Publications (1)

Publication Number Publication Date
CA2796884A1 true CA2796884A1 (fr) 2002-08-15

Family

ID=26952450

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2433915A Expired - Fee Related CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2685214A Expired - Fee Related CA2685214C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2796884A Abandoned CA2796884A1 (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2433915A Expired - Fee Related CA2433915C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree
CA2685214A Expired - Fee Related CA2685214C (fr) 2001-02-08 2002-02-08 Forme posologique orale a liberation regulee amelioree

Country Status (3)

Country Link
EP (1) EP1357898A4 (fr)
CA (3) CA2433915C (fr)
WO (1) WO2002062299A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
CA2601800C (fr) * 2005-03-14 2013-12-03 Nitin Bhalachandra Dharmadhikari Systeme d'administration de medicament par voie orale
CN101534795B (zh) 2006-11-21 2013-04-03 麦克内尔-Ppc股份有限公司 改进释放的镇痛悬浮液
US9833510B2 (en) 2007-06-12 2017-12-05 Johnson & Johnson Consumer Inc. Modified release solid or semi-solid dosage forms
KR20140069381A (ko) 2009-06-02 2014-06-10 다우 글로벌 테크놀로지스 엘엘씨 서방출 투여형
CN110200947A (zh) * 2019-06-27 2019-09-06 深圳市泛谷药业股份有限公司 一种安非他酮肠溶缓释微丸胶囊及其制备方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG42869A1 (en) * 1992-08-05 1997-10-17 Faulding F H & Co Ltd Pelletised pharmaceutical composition
GB9217295D0 (en) * 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US6270805B1 (en) * 1998-11-06 2001-08-07 Andrx Pharmaceuticals, Inc. Two pellet controlled release formulation for water soluble drugs which contains an alkaline metal stearate
US6210716B1 (en) * 1999-02-26 2001-04-03 Andrx Pharmaceuticals, Inc. Controlled release bupropion formulation

Also Published As

Publication number Publication date
WO2002062299A2 (fr) 2002-08-15
EP1357898A4 (fr) 2005-07-13
WO2002062299A3 (fr) 2003-04-24
CA2433915A1 (fr) 2002-08-15
CA2685214C (fr) 2013-01-22
EP1357898A2 (fr) 2003-11-05
CA2433915C (fr) 2010-04-20
CA2685214A1 (fr) 2002-08-15

Similar Documents

Publication Publication Date Title
US8747898B2 (en) Controlled release oral dosage form
US6589553B2 (en) Controlled release oral dosage form
JP6815358B2 (ja) 時限パルス放出システム
JP2637981B2 (ja) 吸収制御薬剤組成物
US7674479B2 (en) Sustained-release bupropion and bupropion/mecamylamine tablets
JP4749639B2 (ja) 味がマスクされ、活性成分を即時放出する、被覆された顆粒の製造方法
CA2686094A1 (fr) Methode de fabrication d'un element semiconducteur
AU757915B2 (en) Controlled release bupropion formulation
CZ296964B6 (cs) Farmaceutické formulace tramadolu v násobných jednotkách a zpusob jejich výroby
JP2004512296A (ja) メチルフェニデート改変放出製剤
JP2008303223A (ja) 脈動用量薬剤経口送達システム
JPH0476966B2 (fr)
CA2011919A1 (fr) Materiel d'enrobage regulant la liberation d'une substance active pour les medicaments a action prolongee
HUE029680T2 (en) Dispensing systems containing weakly basic active ingredients and organic acids
HU227490B1 (en) Sustained release pharmaceutical preparation containing carvedilol
US20030035840A1 (en) Controlled release oral dosage form
EP1711169B1 (fr) Minicomprimes revetus a liberation prolongee de chlorhydrate de venlafaxine
WO2007117110A2 (fr) Granules à libération prolongée contenant du chlorhydrate de tamsulosine et leurs procédés de préparation
CA2685214C (fr) Forme posologique orale a liberation regulee amelioree
WO2013181292A1 (fr) Formulations de nitisinone
AU2002253907A1 (en) Improved controlled release oral dosage form
JP2005510449A (ja) 改良型制御放出経口剤形
KR20060136409A (ko) 벤라팍신 히드로클로라이드의 방출연장형 코팅 미니정제
AU2013273835A1 (en) Timed, pulsatile release systems

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20121127

FZDE Dead

Effective date: 20151126